On the heels of its COVID-19 test, the firm is developing a multiplex test for flu/COVID-19 and targeting tests for Streptococcus and STIs.
The company is working to expand the test menus on its instruments and capitalizing on new placements to gain further market share.
The organization recommended that federal agencies request input from diagnostic industry stakeholders, such as laboratories, manufacturers, and insurers.
Palmetto GBA has expanded its decisions to cover classes of tests, rather than just one test, a move welcomed by most, but not all, of the industry.
The program sequenced 77 genes from more than 10,000 patients and determined how to implement the data into the medical center's electronic medical record.
Many firms that had switched to COVID-19 testing throughout the pandemic as demand soared are now reevaluating their business strategies.
The molecular diagnostic firm has also begun international commercialization of its products in Canada and Singapore.
The Northwestern University spinout's COVID-19 test returns results in 15 minutes using a single-use cartridge and portable analyzer.
The study looked at Black patients with the APOL1 genotype, a signifier of increased risk of kidney failure.
The company has launched its lower-throughput Cobas 5800 instrument in Europe and plans to launch the Digital LightCycler in Q3.